Receptor-mediated targeting of toxins to intraerythrocytic parasite Plasmodium falciparum

Advanced Drug Delivery Reviews

Volumn 41, Issue 2, 2000, Pages 163-170

  Surolia, Namita ^a  

^a JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH   (India)

Author keywords

Malaria; Plasmodium falciparum; Receptor directed targeting; Toxins

Indexed keywords

CELL MEMBRANES; DISEASES; DRUG DOSAGE; IMMUNOLOGY; VACCINES;

CYTOTOXIC EFFECTS; INTRAERYTHROCYTIC PARASITE; MALARIA; PLASMODIUM FALCIPARUM; RECEPTOR MEDIATED TARGETING; TOXINS;

CONTROLLED DRUG DELIVERY;

ANTIMALARIAL AGENT; CHLOROQUINE; IMMUNOTOXIN; MONOCLONAL ANTIBODY; PRIMAQUINE; RICIN A; TRANSFERRIN RECEPTOR;

ERYTHROCYTE; INTERNALIZATION; MALARIA; MEMBRANE TRANSPORT; NONHUMAN; PLASMODIUM FALCIPARUM; PREVALENCE; PRIORITY JOURNAL; REVIEW;

EID: 0343938831     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(99)00063-0     Document Type: Article

References (48)

1. Tyrrell D.A., Heath T.D., Colley C.M., Ryman B.E. New aspects of liposomes. Biochim. Biophys. Acta. 457:1976;259-302.
2. Alving C.R., Steck E.A. The use of liposome-encapsulated drugs in leishmaniasis. Trends Biochem. Sci. 4:1979;N175-N176.
3. Pastan I., Chaudhary V.K., Fitz Gerald D.J. Recombinant toxins as novel therapeutic agents. Annu. Rev. Biochem. 1:1992;331-354.
4. Alving C.R., Schneider I., Swartz J.M. Jr., Steck E.A. Sporozoite induced malaria: therapeutic effects of glycolipids in liposomes. Science. 205:1979;1142-1144.
5. Agarwal A.K., Singhal A., Gupta C.M. Functional drug targeting to erythrocytes in vivo using antibody bearing liposomes as drug vehicles. Biochem. Biophys. Res. Commun. 148:1987;357-361.
6. Singh A.M., Owais M., Varshney G.C. Use of specific polyclonal antibodies for site specific drug targeting to malaria infected erythrocytes in vivo. Indian J. Biochem. Biophys. 30:1993;411-413.
7. Stirpe F., Olsnes S., Pihl A. Gelonin a new inhibitor of protein synthesis, non-toxic to intact cells. J. Biol. Chem. 255:1980;6947-6953.
8. Olsnes S., Pihl A. Cuatrecasas P. Receptors and Recognition. Vol. 1:1976;129-173 Chapman and Hall, London. Series B.
9. Montanaro L., Sperti S., Zambori M.C., Denaro M., Tastoni G., Gasperi-Campari A., Stripe F. Effect of modeccin on the steps of peptide chain elongation. Biochem. J. 176:1978;371-379.
10. Yamaizumi M., Mekada E., Uchida Y., Okada Y. One molecule Diphtheria toxin fragment A introduced into a cell can kill the cell. Cell. 15:1978;245-250.
11. Eiklid K., Olsnes S., Pihl A. Entry of lethal doses of abrin, ricin and modeccin in to the cytosol of HeLa cells. Exp. Cell Res. 126:1980;321-336.
12. Hertler A.A., Frankel A.E. Immunotoxins: a clinical review of their use in the treatment of malignancies. J. Clin. Oncol. 7:1989;1932-1942.
13. Fitz Gerald D., Pastan I. Targeted toxin therapy for the treatment of cancer. J. Natl. Cancer Inst. L81:1989;1455-1463.
14. Vitetta E.S., Fulton R.J., May R.D., Till M., Uhr J.W. Redesigning nature's poisons to create anti-tumor reagents. Science. 238:1987;1098-1104.
15. Pastan I., Fitz Gerald D. Recombinant toxins for cancer treatment. Science. 254:1991;1173-1177.
16. Wawrzynezak E.J. Systemic immunotoxin therapy of cancer: advances and prospects. Br. J. Cancer. 64:1991;624-630.
17. Weil-Hillman G., Runge W., Jansen F.K., Vallera D.A. Cytotoxic effect of anti-Mr 67,000 protein immunotoxins on human tumors in a nude mouse model. Cancer Res. 45:1985;1328-1336.
18. FitzGerald D.J.P., Bjorn M.J., Ferris R.J., Winkelhake J.L., Frankel A.E., Hamilton T.C., Ozols R.F., Willingham M.C., Pastan I. Antitumor activity of two immunotoxins directed against human ovarian cancer cells in nude mice. Cancer Res. 47:1987;1407-1410.
19. Olsnes S., Sandwig K. Entry of polypeptide toxins into mammalian cells. Pastan I., Willinghan P. Endocytosis. 1985;195-234 Plenum Press, New York.
20. Middlebrook J.L., Dorland R.B. Bacterial toxins: cellular mechanisms of action. Microbiol. Rev. 48:1984;199-221.
21. Willingham M.C., Pastan I. The transmit of epidermal growth factor through coated pit of the Golgi system. J. Cell Biol. 94:1982;207-212.
22. Ren J., Kachel K., Kim H., Malenbaum S.E., Collier R.T., London E. Interaction of diphtheria toxin T domain with molten globule-like proteins and its implication for translocation. Science. 284:1999;955-957.
23. Krupakar J., Swaminathan C.P., Das P.K., Surolia A., Podder S.K. Calorimetric studies on the stability of the ribosome-inactivating protein abrin. II. Effects of pH and ligand binding. Biochem. J. 338:1999;273-279.
24. Hazes B., Read R.J. Accumulating evidence suggests the endoplasmic reticulum-associated protein degradation pathway to enter target cell. Biochemistry. 36:1997;11051-11054.
25. Gormley J.A., Howard R.J., Taraschi T.F. Trafficking of malarial proteins to the host cell cytoplasm and erythrocyte surface membrane involves multiple pathways. J. Cell Biol. 119:1992;1481-1495.
26. Trowbridge I.S., Domingo D.L. Anti-transferrin receptor monoclonal antibody and toxin-antibody conjugates affect growth of human tumor cells. Nature (Lond.). 294:1981;171-173.
27. Zovickian J., Johnson V.J., Youle R.J. Potent and specific killing of human malignant brain tumor cells by an anti-transferrin receptor antibody-ricin immunotoxin. J. Neurosurg. 66:1987;850-861.
28. Galbraith G.M.P., Galbraith R.M., Faulk W.P. Transferrin binding by human lymphoblastoid cell lines and other transformed cells. Cell Immunol. 49:1980;215-222.
29. Trowbridge I.S., Newman R.A., Domingo D.L., Sanvage C. Transferrin receptors: structure and function. Biochem. Pharmacol. 33:1984;925-932.
30. Gatter K.C., Brown G., Trowbridge I.S., Wollston R.E., Mason D.Y. Transferrin receptors in human tissues: their distribution and possible clinical relevance. J. Clin. Pathol. 36:1983;539-545.
31. Sutherland R., Delia D., Schneider C., Newman R., Kemshed J., Greaves M. Ubiquitous cell-surface glycoprotein on tumor cells is proliferation-associated receptor for transferrin. Proc. Natl. Acad. Sci. USA. 78:1981;4515-4519.
32. Hall W.A., Merrill M.J., Walbridge S., Youle R.J. Epidermal growth factor receptors on ependymomas and other brain tumors. J. Neurosurg. 72:1990;641-646.
33. Recht L., Torres C.O., Smith T.W., Raso V., Griffin T.W. Transferrin receptor in normal and neoplastic brain tissue: implications for brain-tumor immunotherapy. J. Neurosurg. 72:1990;941-945.
34. Masawe A.E.J., Muindi D.M., Suai G.B.R. Infections in iron deficiency and other types of anemia in the tropics. Lancet. ii:1974;314-317.
35. Raventos-Suarez C., Pollack S., Nagel R.L. Plasmodium falciparum inhibition of in vitro growth by desferrioxamine. Am. J. Trop. Med. Hyg. 31:1982;919-922.
36. Harvey P.W.J., Bell R.G., Nesheim M.C. Iron deficiency protects inbred mice against infection with Plasmodium chabaudi. Infect. Immun. 50:1985;932-934.
37. Fritsch G., Treumer J., Spira D.T., Jung A. Plasmodium vinckeii, suppression of mouse infection with desferrioxamine B. Exp. Parasitol. 60:1985;171-174.
38. Pollack S., Fleming J. Plasmodium falciparum takes up iron from transferrin. Br. J. Haematol. 58:1984;289-293.
39. Lodish H.F., Small B. Membrane proteins synthesized by rabbit reticulocytes. J. Cell Biol. 65:1975;51-64.
40. Elford B.C., Cowan G.M., Ferguson D.J.P. Parasite-regulated membrane transport processes and metabolic control in malaria-infected erythrocytes. Biochem. J. 308:1995;361-374.
41. Lauer S.A., Rathod P.K., Ghori N., Haldar K. A membrane network for nutrient import in red cells infected with the malaria parasite. Science. 276:1997;1122-1125.
42. Fitz Gerald D.J., Willingham M.C., Pastan I. Antitumor effects of an immunotoxin made with Pseudomonas exotoxin in a nude mouse model of human ovarian cancer. Proc. Natl. Acad. Sci. USA. 83:1986;6627-6630.
43. Rodriguez M.H., Jungery M. A protein on Plasmodium falciparum infected erythrocytes functions as a transferrin receptor. Nature. 324:1986;388-391.
44. Pollack S., Schnelle V. Inability to detect transferrin receptors on P. falciparum parasitized red cells. Br. J. Haematol. 68:1988;125-129.
45. Haldar K., Henderson C.L., Cross G.A.M. Identification of the parasite transferrin receptor of Plasmodium falciparum infected erythrocytes and its acylation via 1,2-diacyl-L-sn-glycerol. Proc. Natl. Acad. Sci. USA. 83:1986;8565-8569.
46. Surolia N., Misquith S. Cell surface receptor directed targeting of toxin to human malaria parasite, Plasmodium falciparum. FEBS Lett. 396:1996;57-61.
47. Steck P.J., Wallach D.F.H. The binding of kidney-bean phytohemagglutinin by Ehrlich Ascites Carcinoma. Biochim. Biophys. Acta. 97:1965;510-522.
48. Surolia N., Karthikeyan G., Padmanaban G. Role of cytochrome P-450 in conferring chloroquine resistance to the malaria parasite. Biochem. Biophys. Res. Commun. 197:1993;562-569.